EA201790160A1 - Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d - Google Patents

Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d

Info

Publication number
EA201790160A1
EA201790160A1 EA201790160A EA201790160A EA201790160A1 EA 201790160 A1 EA201790160 A1 EA 201790160A1 EA 201790160 A EA201790160 A EA 201790160A EA 201790160 A EA201790160 A EA 201790160A EA 201790160 A1 EA201790160 A1 EA 201790160A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
caused
virus
methods
viruses
Prior art date
Application number
EA201790160A
Other languages
English (en)
Other versions
EA036745B1 (ru
Inventor
Эндрю Вайан
Original Assignee
Репликор Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790160(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Репликор Инк. filed Critical Репликор Инк.
Publication of EA201790160A1 publication Critical patent/EA201790160A1/ru
Publication of EA036745B1 publication Critical patent/EA036745B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Раскрыт способ лечения инфекции, вызванной вирусом гепатита В, или коинфекции, вызванной вирусом гепатита В/вирусом гепатита дельта, способ, включающий введение субъекту, нуждающемуся в подобном лечении, первого фармацевтически приемлемого средства, которое содержит по меньшей мере один тиофосфатный полимер нуклеиновой кислоты, и второго фармацевтически приемлемого средства, которое содержит по меньшей мере один нуклеозидный/нуклеотидный аналог-ингибитор полимеразы вируса гепатита В.
EA201790160A 2014-07-10 2015-07-07 Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d EA036745B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Publications (2)

Publication Number Publication Date
EA201790160A1 true EA201790160A1 (ru) 2017-06-30
EA036745B1 EA036745B1 (ru) 2020-12-16

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790160A EA036745B1 (ru) 2014-07-10 2015-07-07 Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d

Country Status (32)

Country Link
US (1) US9603865B2 (ru)
EP (1) EP3166615B1 (ru)
JP (2) JP2017521433A (ru)
KR (2) KR20230070330A (ru)
CN (2) CN113750112A (ru)
AU (1) AU2015286199B2 (ru)
BR (1) BR112017000320B1 (ru)
CA (1) CA2954182C (ru)
CL (1) CL2017000008A1 (ru)
CU (1) CU20170001A7 (ru)
DK (1) DK3166615T3 (ru)
DO (1) DOP2017000002A (ru)
EA (1) EA036745B1 (ru)
EC (1) ECSP16097355A (ru)
ES (1) ES2963814T3 (ru)
FI (1) FI3166615T3 (ru)
HK (1) HK1231402A1 (ru)
HR (1) HRP20231400T1 (ru)
HU (1) HUE064449T2 (ru)
IL (1) IL249660B (ru)
LT (1) LT3166615T (ru)
MD (1) MD4760C8 (ru)
MX (1) MX2017000053A (ru)
MY (1) MY178087A (ru)
PH (1) PH12017500010A1 (ru)
PL (1) PL3166615T3 (ru)
PT (1) PT3166615T (ru)
RS (1) RS64833B1 (ru)
SG (1) SG11201700073PA (ru)
SI (1) SI3166615T1 (ru)
TW (1) TWI766831B (ru)
WO (1) WO2016004525A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005357A (es) * 2018-11-08 2021-06-30 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos.
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN113620993A (zh) * 2020-05-07 2021-11-09 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦d晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816A (zh) * 2020-07-30 2022-02-18 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
EP4247393A1 (en) * 2020-11-20 2023-09-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
EP1537208A1 (en) 2002-09-13 2005-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2006091798A2 (en) * 2005-02-22 2006-08-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus
WO2012021985A1 (en) 2010-08-20 2012-02-23 Replicor Inc. Oligonucleotide chelate complexes
US9260471B2 (en) * 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
BR112014028654A2 (pt) * 2012-05-18 2017-10-10 Replicor Inc composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos
WO2014032176A1 (en) * 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
JP2017521433A (ja) 2017-08-03
EA036745B1 (ru) 2020-12-16
SI3166615T1 (sl) 2023-12-29
WO2016004525A1 (en) 2016-01-14
EP3166615A1 (en) 2017-05-17
JP2020143065A (ja) 2020-09-10
MD4760B1 (ru) 2021-07-31
SG11201700073PA (en) 2017-02-27
PL3166615T3 (pl) 2024-02-19
FI3166615T3 (fi) 2023-11-06
ES2963814T3 (es) 2024-04-02
AU2015286199B2 (en) 2020-05-14
CL2017000008A1 (es) 2017-06-09
HK1231402A1 (zh) 2017-12-22
CU20170001A7 (es) 2017-04-05
IL249660B (en) 2022-02-01
KR20170029577A (ko) 2017-03-15
IL249660A0 (en) 2017-02-28
DOP2017000002A (es) 2017-03-15
US9603865B2 (en) 2017-03-28
US20160008393A1 (en) 2016-01-14
TWI766831B (zh) 2022-06-11
HUE064449T2 (hu) 2024-03-28
BR112017000320A2 (pt) 2017-11-07
EP3166615B1 (en) 2023-08-09
DK3166615T3 (da) 2023-11-13
HRP20231400T1 (hr) 2024-02-16
CA2954182C (en) 2023-08-15
MX2017000053A (es) 2017-05-01
ECSP16097355A (es) 2017-03-31
LT3166615T (lt) 2024-01-25
CN113750112A (zh) 2021-12-07
EP3166615A4 (en) 2018-01-17
AU2015286199A1 (en) 2017-02-23
BR112017000320B1 (pt) 2023-02-07
PT3166615T (pt) 2023-11-13
CA2954182A1 (en) 2016-01-14
RS64833B1 (sr) 2023-12-29
MD4760C8 (ru) 2022-02-28
MD20170014A2 (ru) 2017-07-31
CN106659730A (zh) 2017-05-10
KR20230070330A (ko) 2023-05-22
TW201613617A (en) 2016-04-16
JP6922030B2 (ja) 2021-08-18
PH12017500010A1 (en) 2017-05-15
MY178087A (en) 2020-10-02

Similar Documents

Publication Publication Date Title
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
PH12018500931A1 (en) Hcv polymerase inhibitors
EA201790597A1 (ru) Способы лечения вирусных инфекций filoviridae
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
MX2021006635A (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas.
EA201890731A1 (ru) Модуляторы корового белка гепатита b
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
EA201600226A1 (ru) Способы и композиции для рнк-направленного лечения вич-инфекции
EA201990628A1 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
EA201891975A1 (ru) Тиазолидные соединения для лечения вирусных инфекций
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
EA201790778A1 (ru) Фармацевтические композиции длительного действия от гепатита с
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
MA40218A (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d
EA202191771A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ RNAi ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
TH168570B (th) วิธีการของการเตรียมนิวคลิโอไทด์อนาล็อกที่ถูกแทนที่
EA202092602A2 (ru) -d-2'-дезокси-2'--фтор-2'--c-замещенные-2-модифицированные-n6-замещенные пуриновые нуклеотиды для лечения вызванных hcv заболеваний
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в
TH1601005264A (ru)
TH182360B (th) นิวคลีโอไซต์, นิวคลีโอไทด์ ที่ถูกแทนที่ และ สารคล้ายคลึงของสิ่งนั้น